Corcept Therapeutics CORT Pre-Tax Income
Pre-Tax Income at other companies
Other financials
Where this comes from
Reported directly by Corcept Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest.
The official record: Corcept Therapeutics’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →
Ask your AI about Corcept Therapeutics's pre-tax income.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Corcept Therapeutics's pre-tax income?
- Corcept Therapeutics (CORT) reported pre-tax income of -$44.72M in Q1 2026.
- How has Corcept Therapeutics's pre-tax income changed year-over-year?
- Corcept Therapeutics's pre-tax income decreased by 564.9% year-over-year, from $9.62M to -$44.72M.
- What is the long-term trend for Corcept Therapeutics's pre-tax income?
- Over 4 years (2021 to 2025), Corcept Therapeutics's pre-tax income has grown at a -14.6% compound annual growth rate (CAGR), from $125.01M to $66.46M.
- What does pre-tax income mean?
- Total profit before accounting for income taxes.
- How do you interpret pre-tax income?
- Reflects the total pre-tax profitability of the business, useful for comparing performance across different tax jurisdictions.
- How does pre-tax income compare across companies?
- Standard metric for assessing pre-tax performance across global peers with varying tax rates.